Skip to content
Disclosery

Cutter Capital Management, LP

Follow

13F filer, CIK 1983313, NEW YORK, NY

Cutter Capital Management, LP reported $331,287,284 across 27 holdings for the quarter ended 2024-06-30, in a 13F-HR filed 2024-08-14. Its ten largest share positions make up 55.88% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001214659-24-014671

Period
2024-06-30
Reported value
$331M
Holdings
27
Top 10 weight
55.88%
New
13
Sold out
12

Largest buys vs the previous quarter

SecurityShares changeApprox. value
MRKnew+175,600$21.7M
AMGNnew+64,201$20.1M
KVUEnew+960,400$17.5M
RAREnew+365,000$15M
CYTKnew+236,900$12.8M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
BMYexited-446,900-$24.2M
REGNexited-16,360-$15.7M
ACADexited-658,409-$12.2M
HALOexited-255,049-$10.4M
EXELexited-398,762-$9.46M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q2 2024

Share positions as resolved from 13F-HR 0001214659-24-014671, largest first. % of portfolio is the value over $328,127,284, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
BMRNBIOMARIN PHARMACEUTICAL INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: not loaded; 2023Q4: 129,906 shares; 2024Q1: 175,000 shares; 2024Q2: 273,533 shares 273,533$22.5M6.86%+98,533Timeline
MRKMERCK & CO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: not loaded; 2023Q4: 136,098 shares; 2024Q1: not reported; 2024Q2: 175,600 shares 175,600$21.7M6.63%newTimeline
GILDGILEAD SCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: not loaded; 2023Q4: not reported; 2024Q1: 265,436 shares; 2024Q2: 292,959 shares 292,959$20.1M6.13%+27,523Timeline
AMGNAMGEN INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: not loaded; 2023Q4: 57,381 shares; 2024Q1: not reported; 2024Q2: 64,201 shares 64,201$20.1M6.11%newTimeline
RPRXROYALTY PHARMA PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: not loaded; 2023Q4: 370,000 shares; 2024Q1: 411,540 shares; 2024Q2: 692,300 shares 692,300$18.3M5.56%+280,760Timeline
BIIBBIOGEN INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: not loaded; 2023Q4: not reported; 2024Q1: 52,000 shares; 2024Q2: 76,726 shares 76,726$17.8M5.42%+24,726Timeline
KVUEKENVUE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: not loaded; 2023Q4: not reported; 2024Q1: not reported; 2024Q2: 960,400 shares 960,400$17.5M5.32%newTimeline
INSMINSMED INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: not loaded; 2023Q4: 413,499 shares; 2024Q1: 227,337 shares; 2024Q2: 227,637 shares 227,637$15.3M4.65%+300Timeline
LEGNLEGEND BIOTECH CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: not loaded; 2023Q4: not reported; 2024Q1: 79,830 shares; 2024Q2: 343,130 shares 343,130$15.2M4.63%+263,300Timeline
RAREULTRAGENYX PHARMACEUTICAL INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: not loaded; 2023Q4: not reported; 2024Q1: not reported; 2024Q2: 365,000 shares 365,000$15M4.57%newTimeline
TEVATEVA PHARMACEUTICAL INDS LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: not loaded; 2023Q4: 1,061,668 shares; 2024Q1: 1,135,710 shares; 2024Q2: 911,900 shares 911,900$14.8M4.52%-223,810Timeline
SRPTSAREPTA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: not loaded; 2023Q4: not reported; 2024Q1: 94,379 shares; 2024Q2: 89,379 shares 89,379$14.1M4.3%-5,000Timeline
CYTKCYTOKINETICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: not loaded; 2023Q4: not reported; 2024Q1: not reported; 2024Q2: 236,900 shares 236,900$12.8M3.91%newTimeline
BCRXBIOCRYST PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: not loaded; 2023Q4: 1,521,812 shares; 2024Q1: 2,105,459 shares; 2024Q2: 1,975,298 shares 1,975,298$12.2M3.72%-130,161Timeline
CRSPCRISPR THERAPEUTICS AGQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: not loaded; 2023Q4: 107,500 shares; 2024Q1: 120,185 shares; 2024Q2: 201,497 shares 201,497$10.9M3.32%+81,312Timeline
ACLXARCELLX INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: not loaded; 2023Q4: not reported; 2024Q1: 107,000 shares; 2024Q2: 187,000 shares 187,000$10.3M3.15%+80,000Timeline
AVADEL PHARMACEUTICALSAVADEL PHARMACEUTICALSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: not loaded; 2023Q4: not reported; 2024Q1: 541,926 shares; 2024Q2: 733,001 shares 733,001$10.3M3.14%+191,075
HRMYHARMONY BIOSCIENCES HLDGS INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: not loaded; 2023Q4: not reported; 2024Q1: not reported; 2024Q2: 295,771 shares 295,771$8.92M2.72%newTimeline
AVTRAVANTOR INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: not loaded; 2023Q4: not reported; 2024Q1: not reported; 2024Q2: 400,000 shares 400,000$8.48M2.58%newTimeline
VERAVERA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: not loaded; 2023Q4: not reported; 2024Q1: not reported; 2024Q2: 230,000 shares 230,000$8.32M2.54%newTimeline
BBIOBRIDGEBIO PHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: not loaded; 2023Q4: 103,324 shares; 2024Q1: not reported; 2024Q2: 311,700 shares 311,700$7.9M2.41%newTimeline
IONSIONIS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: not loaded; 2023Q4: not reported; 2024Q1: 289,366 shares; 2024Q2: 160,166 shares 160,166$7.63M2.33%-129,200Timeline
ELVNENLIVEN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: not loaded; 2023Q4: not reported; 2024Q1: not reported; 2024Q2: 222,985 shares 222,985$5.21M1.59%newTimeline
PFEPFIZER INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: not loaded; 2023Q4: 265,000 shares; 2024Q1: not reported; 2024Q2: 185,200 shares 185,200$5.18M1.58%newTimeline
EOLSEVOLUS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: not loaded; 2023Q4: not reported; 2024Q1: not reported; 2024Q2: 465,300 shares 465,300$5.05M1.54%newTimeline
PRGOPERRIGO CO PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: not loaded; 2023Q4: 260,000 shares; 2024Q1: 322,114 shares; 2024Q2: 100,000 shares 100,000$2.57M0.78%-222,114Timeline

Options

Puts and calls, as filed. The amount and value describe the underlying shares, not the option premium, so they stay out of % of portfolio (H5).

SecurityTypeAmountValueChange
SRPTSAREPTA THERAPEUTICS INC COMcall20,000$3.16Mnew

Sold out in Q2 2024

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
BMYBRISTOL-MYERS SQUIBB CO446,900$24.2Mshares
REGNREGENERON PHARMACEUTICALS16,360$15.7Mshares
ACADACADIA PHARMACEUTICALS INC658,409$12.2Mshares
HALOHALOZYME THERAPEUTICS INC255,049$10.4Mshares
EXELEXELIXIS INC398,762$9.46Mshares
LLYELI LILLY & CO11,040$8.59Mshares
AGIOAGIOS PHARMACEUTICALS INC288,580$8.44Mshares
VRDNVIRIDIAN THERAPEUTICS INC278,638$4.88Mshares
KYTXKYVERNA THERAPEUTICS INC166,514$4.14Mshares
PLRXPLIANT THERAPEUTICS INC194,119$2.89Mshares
CABACABALETTA BIO INC157,964$2.69Mshares
IRWDIRONWOOD PHARMACEUTICALS INC250,000$2.18Mcall

How Q2 2024 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001214659-24-014671 base2024-08-14acceptance time not in the bulk data set